Clinical characteristics of patients with COVID-19 harboring detectable intracellular SARS-CoV-2 RNA in peripheral blood cells
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: Although SARS-CoV-2 RNAemia has been reported to strongly impact patients with severe COVID-19, the clinical characteristics of patients with COVID-19 harboring detectable intracellular SARS-CoV-2 RNA remain unknown.
METHODS: We included adult patients who had developed COVID-19 between February and September 2020. Total white blood cells derived from the buffy coat of peripheral whole blood were used to detect SARS-CoV-2 RNA using the Illumina COVIDSeq test. We compared the clinical characteristics between patients with and without detected viral RNA (detected and undetected groups).
RESULTS: Among the 390 patients included, 17 harbored SARS-CoV-2 RNA in peripheral white blood cells. All 17 patients required oxygen support during the disease course and had higher intensive care unit admission (52.9% vs 28.9%, P = 0.035), mortality (17.7% vs 3.5%, P = 0.004), kidney dysfunction (severe, 23.5% vs 6.4%, P = 0.029), and corticosteroid treatment rates (76.5% vs 46.5%, P = 0.016) than those of patients in the undetected group.
CONCLUSION: We propose that patients with circulating intracellular SARS-CoV-2 RNA in the peripheral blood exhibited the most severe disease course.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:135 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 135(2023) vom: 15. Okt., Seite 41-44 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tanaka, Hiromu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 29.09.2023 Date Revised 29.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2023.07.030 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360411118 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360411118 | ||
| 003 | DE-627 | ||
| 005 | 20231226082945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2023.07.030 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360411118 | ||
| 035 | |a (NLM)37541421 | ||
| 035 | |a (PII)S1201-9712(23)00680-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tanaka, Hiromu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical characteristics of patients with COVID-19 harboring detectable intracellular SARS-CoV-2 RNA in peripheral blood cells |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2023 | ||
| 500 | |a Date Revised 29.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: Although SARS-CoV-2 RNAemia has been reported to strongly impact patients with severe COVID-19, the clinical characteristics of patients with COVID-19 harboring detectable intracellular SARS-CoV-2 RNA remain unknown | ||
| 520 | |a METHODS: We included adult patients who had developed COVID-19 between February and September 2020. Total white blood cells derived from the buffy coat of peripheral whole blood were used to detect SARS-CoV-2 RNA using the Illumina COVIDSeq test. We compared the clinical characteristics between patients with and without detected viral RNA (detected and undetected groups) | ||
| 520 | |a RESULTS: Among the 390 patients included, 17 harbored SARS-CoV-2 RNA in peripheral white blood cells. All 17 patients required oxygen support during the disease course and had higher intensive care unit admission (52.9% vs 28.9%, P = 0.035), mortality (17.7% vs 3.5%, P = 0.004), kidney dysfunction (severe, 23.5% vs 6.4%, P = 0.029), and corticosteroid treatment rates (76.5% vs 46.5%, P = 0.016) than those of patients in the undetected group | ||
| 520 | |a CONCLUSION: We propose that patients with circulating intracellular SARS-CoV-2 RNA in the peripheral blood exhibited the most severe disease course | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Intracellular SARS-CoV-2 RNA | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Namkoong, Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Chubachi, Shotaro |e verfasserin |4 aut | |
| 700 | 1 | |a Irie, Shinji |e verfasserin |4 aut | |
| 700 | 1 | |a Uwamino, Yoshifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Azekawa, Shuhei |e verfasserin |4 aut | |
| 700 | 1 | |a Otake, Shiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nakagawara, Kensuke |e verfasserin |4 aut | |
| 700 | 1 | |a Fukushima, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Watase, Mayuko |e verfasserin |4 aut | |
| 700 | 1 | |a Kusumoto, Tatsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Masaki, Katsunori |e verfasserin |4 aut | |
| 700 | 1 | |a Kamata, Hirofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Ishii, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Yukinori |e verfasserin |4 aut | |
| 700 | 1 | |a Takano, Tomomi |e verfasserin |4 aut | |
| 700 | 1 | |a Imoto, Seiya |e verfasserin |4 aut | |
| 700 | 1 | |a Koike, Ryuji |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Akinori |e verfasserin |4 aut | |
| 700 | 1 | |a Miyano, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Ogawa, Seishi |e verfasserin |4 aut | |
| 700 | 1 | |a Kanai, Takanori |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Taka-Aki |e verfasserin |4 aut | |
| 700 | 1 | |a Fukunaga, Koichi |e verfasserin |4 aut | |
| 700 | 0 | |a Japan COVID-19 Task Force |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 135(2023) vom: 15. Okt., Seite 41-44 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:135 |g year:2023 |g day:15 |g month:10 |g pages:41-44 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2023.07.030 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 135 |j 2023 |b 15 |c 10 |h 41-44 | ||